123 related articles for article (PubMed ID: 8795070)
21. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
22. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of glomerular AT1 receptors in rats with myocardial infarction.
Mento PF; Pica ME; Hilepo J; Chang J; Hirsch L; Wilkes BM
Am J Physiol; 1998 Oct; 275(4):H1247-53. PubMed ID: 9746472
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats.
Lee J; Kim S; Jung M; Oh Y; Kim SW
Clin Exp Pharmacol Physiol; 2002 Apr; 29(4):299-303. PubMed ID: 11985539
[TBL] [Abstract][Full Text] [Related]
25. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Kato S; Luyckx VA; Ots M; Lee KW; Ziai F; Troy JL; Brenner BM; MacKenzie HS
Kidney Int; 1999 Sep; 56(3):1037-48. PubMed ID: 10469372
[TBL] [Abstract][Full Text] [Related]
27. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Kuro T; Okahara A; Nose M; Ikuse T; Matsumura Y
Biol Pharm Bull; 2000 Jul; 23(7):820-5. PubMed ID: 10919359
[TBL] [Abstract][Full Text] [Related]
28. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
29. AT1 receptor expression in glomeruli from NO-deficient rats.
Vandermeersch S; Stefanovic V; Hus-Citharel A; Ardaillou R; Dussaule JC; Chansel D
Nephron Exp Nephrol; 2003; 95(3):e119-28. PubMed ID: 14646364
[TBL] [Abstract][Full Text] [Related]
30. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis.
Wolf G; Schneider A; Helmchen U; Stahl RA
Exp Nephrol; 1998; 6(2):112-20. PubMed ID: 9567217
[TBL] [Abstract][Full Text] [Related]
31. Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension.
Chen K; Zhang X; Dunham EW; Zimmerman BG
Hypertension; 1996 Jan; 27(1):85-9. PubMed ID: 8591894
[TBL] [Abstract][Full Text] [Related]
32. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
Karam H; Clozel JP; Bruneval P; Gonzalez MF; Ménard J
Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.
Chamorro V; Wangensteen R; Sainz J; Duarte J; O'Valle F; Osuna A; Vargas F
Clin Sci (Lond); 2004 Mar; 106(3):251-9. PubMed ID: 14521506
[TBL] [Abstract][Full Text] [Related]
34. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
[TBL] [Abstract][Full Text] [Related]
35. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats.
Yamada T; Kuno A; Masuda K; Ogawa K; Sogawa M; Nakamura S; Ando T; Sano H; Nakazawa T; Ohara H; Nomura T; Joh T; Itoh M
J Pharmacol Exp Ther; 2003 Oct; 307(1):17-23. PubMed ID: 12944495
[TBL] [Abstract][Full Text] [Related]
36. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats.
Kubo T; Ibusuki T; Saito E; Kambe T; Hagiwara Y
Eur J Pharmacol; 2000 Jul; 400(2-3):231-7. PubMed ID: 10988339
[TBL] [Abstract][Full Text] [Related]
37. No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.
Uijl E; Ren L; Mirabito Colafella KM; van Veghel R; Garrelds IM; Domenig O; Poglitsch M; Zlatev I; Kim JB; Huang S; Melton L; Hoorn EJ; Foster D; Danser AHJ
Clin Sci (Lond); 2021 Jan; 135(2):259-274. PubMed ID: 33404046
[TBL] [Abstract][Full Text] [Related]
38. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
[TBL] [Abstract][Full Text] [Related]
39. Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats.
Asano N; Ogura T; Mimura Y; Otsuka F; Kishida M; Hashimoto M; Yamauchi T; Makino H
Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):171-80. PubMed ID: 9667071
[TBL] [Abstract][Full Text] [Related]
40. Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension.
Naitoh M; Suzuki H; Arakawa K; Matsumoto A; Ichihara A; Matsuda H; Kubota E; Murakami M; Nakamoto H; Saruta T
Am J Physiol; 1997 Feb; 272(2 Pt 2):H679-87. PubMed ID: 9124424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
